Why the study?
Does interferon alpha-2B reduce HCV-RNA in hemophilia patients with chronic hepatitis C?
Does interferon alpha-2B reduce HCV-RNA in hemophilia patients with chronic hepatitis C?
Interferon alpha-2B treatment can clear HCV-RNA in a subset of hemophilia patients with chronic hepatitis C, and HCV-RNA measurement is more sensitive than ALAT for detecting relapse.
Answers are grounded in this paper and cite their sources.
May support HCV-RNA clearance by interferon in some hemophilia patients; hypothesis-generating and should not yet change practice.
To establish the effect of interferon alpha-2B (IFN-alpha) treatment on hepatitis C virus (HCV) viremia, rather than monitor the alanine aminotransferase (ALAT) values we measured HCV-RNA by cDNA-polymerase chain reaction (cDNA-PCR) in plasma before and during IFN-alpha treatment. Eight hemophilia patients with chronic hepatitis C were treated with IFN-alpha for 24 weeks: 5 MU daily for 2 weeks, 2.5 MU daily for 4 weeks, and 1.5 MU three times a week for 18 weeks. HCV-RNA, as measured by cDNA-PCR, was present in all patients before treatment. After 24 weeks of treatment HCV-RNA was no longer detectable in three of eight (37.5%) patients, whereas only one of eight (12.5%) patients showed complete ALAT normalization. In three of eight patients a transient response to IFN-alpha was seen, with renewed HCV-RNA detection after dose reduction. HCV-RNA measurement by cDNA-PCR appeared to be more sensitive in detecting relapse than ALAT measurement.
No takes yet. Share an insight, caveat, or question.
Bresters et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: